The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...
As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...
Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback